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Aims Programmed necrosis (necroptosis) represents a newly identified mechanism of cell death combining features of both
apoptosis and necrosis. Like apoptosis, necroptosis is tightly regulated by distinct signalling pathways. A key regulatory
role in programmed necrosis has been attributed to interactions of the receptor-interacting protein kinases, RIP1 and
RIP3. However, the specific functional role of RIP3-dependent signalling and necroptosis in the heart is unknown. The
aims of this study were thus to assess the significance of necroptosis and RIP3 in the context of myocardial ischaemia.
Methods
and results
Immunoblots revealed strong expression of RIP3 in murine hearts, indicating potential functional significance of this
protein in the myocardium. Consistent with a role in promoting necroptosis, adenoviral overexpression of RIP3 in neo-
natal rat cardiomyocytes and stimulation with TNF-a induced the formation of a complex of RIP1 and RIP3. Moreover,
RIP3 overexpression was sufficient to induce necroptosis of cardiomyocytes. In vivo, cardiac expression of RIP3 was up-
regulated upon myocardial infarction (MI). Conversely, mice deficient for RIP3 (RIP32/2) showed a significantly better
ejection fraction (45+3.6 vs. 32+ 4.4%, P, 0.05) and less hypertrophy in magnetic resonance imaging studies 30 days
after experimental infarction due to left anterior descending coronary artery ligation. This was accompanied by a dimin-
ished inflammatory response of infarcted hearts and decreased generation of reactive oxygen species.
Conclusion Here, we show that RIP3-dependent necroptosis modulates post-ischaemic adverse remodelling in a mouse model of MI.
This novel signalling pathway may thus be an attractive target for future therapies that aim to limit the adverse conse-
quences of myocardial ischaemia.
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1. Introduction
Acute myocardial infarction is one of the leading causes of death world-
wide.1 Despite considerable progress, contemporary therapy can only
partially address the central problem that leads from acute ischaemia
and infarction to chronic heart failure: a major loss of cardiomyocytes
with subsequent remodelling and contractile dysfunction.
Apoptosis, which is mediated by death receptors like the TNF recep-
tor2 or fas receptor/CD95,3 has been considered a possible target for
novel therapies,4 as this process is tightly regulated by specific signalling
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pathways and could thus potentially be inhibited. For example, TNF-a
has been shown to be up-regulated during myocardial infarction (MI)
and to enhance apoptosis in this clinical condition.5 However, the
overall rate of apoptotic cells in the infarcted region was ,1% in this
study and recent theories question a significant role of apoptosis in post-
ischaemic remodelling.6,7 Recently, a novel mechanism called ‘pro-
grammed necrosis’ or necroptosis has been suggested as another im-
portant mediator of cell death in the heart.6 Similar to apoptotic cell
death, this process is tightly regulated by distinct molecules, but leads to
the typical morphological signs of necrosis such as defects of membrane
integrity and inflammation, thus combining features of both mechan-
isms.6,8–11 The signalling pathways that activate programmed necrosis
are not fully understood. However, in vitro studies could demonstrate
that TNF-a-dependent formation of a complex between receptor-
interacting protein 1 (RIP1) and another kinase, receptor-interacting
protein 3 (RIP3) is an essential step for inducing programmed necro-
sis.8,9,12 In this process, RIP3 appears to play a key role, controlling the
phosphorylation of RIP1, a necessary step in programmed necrosis.8,12
An important role of RIP3-mediated necroptosis has been demon-
strated during viral infection of the liver and in tissue damage due to in-
flammatory bowel disease.13 In the heart, inhibition of RIP1 by the small
molecule necrostatin-1 leads to a reduction of infarct size, implying func-
tional importance of necroptosis also in myocardial ischaemia.14– 16 In
contrast, the functional significance of RIP3 in the heart is still
unknown. Here, we demonstrate that RIP3 is expressed in the heart
and RIP3 is activated during MI. Moreover, mice lacking RIP3 reveal
improved cardiac performance, accompanied by a decreased inflamma-
tory response and generation of reactive oxygen species (ROS).
2. Methods
2.1 In vitro experiments
For the preparation of neonatal rat ventricular cardiomyocytes (NRVCMs),
1- to 2-day-old Wistar rats were sacrificed by decapitation and hearts were
immediately removed for digestion with collagenase II (Worthington) at
378C, as previously described.17 Cells were infected with the indicatedmulti-
plicity of infection under serum-free conditions 24 h after plating and
subsequently cultured supplementedwith2% fetal calf serum for48 h.After-
wards, cells were analysed by flow cytometric analysis, immunoblots, MTT
cell viability assays, real-time PCR, immunohistology, or electron micros-
copy (see Supplementary material online for detailed description of
applied methods).
2.2 In vivo studies
RIP3-deficient (RIP32/2) mice,18 kindly provided by Genentech, Inc., South
San Francisco, CA, USA, and littermate WT mice (C57/BL6N-background)
were studied at 10–12 weeks of age. Mice were subjected to permanent left
anterior descending coronary artery (LAD) ligation and subsequently
assessed for left ventricular (LV) morphology and function. Furthermore,
transgenic and WT mouse hearts were analysed by (immuno-)histology
and electron microscopy as well as for the content of ROS. For LAD ligation
as well as heart removal, mice received 0.1 mg Temgesic/kg body weight by
subcutaneous injection for analgesia and were anaesthetized by inhalation of
isoflurane (3–5%). For postoperative analgesia, 0.1 mg Temgesic/kg body
weight was applied once daily for 5 days post-surgery. All studies were
approved by the animal ethics committee of Schleswig-Holstein, Germany.
Magnetic resonance imaging (MRI) experiments were performed as
described elsewhere.19 Detailed methods are available in Supplementary
material online.
2.3 Statistical analysis
All results were expressed as mean+ SEM. We performed statistical ana-
lysis using one- or two-way ANOVA followed by Student–Newman–
Keuls post hoc tests or t-tests as appropriate. A P-value of,0.05 was consid-
ered statistically significant.
3. Results
3.1 RIP3 is expressed in cardiomyocytes and
co-localizes with mitochondria
In order to unravel a potential function of RIP3 in the myocardium, we
first assessed its expression in the heart. While cardiac expression of
RIP3 (55 kDa) was lower compared with spleen and lung, it was signifi-
cantly higher than in brain and kidney (Figure 1A and B). Of note, the
shifted bands above from kDa in liver and kidney might be due to post-
translational modification of RIP3. RIP3 was also expressed in isolated
NRVCMs (Figure 1C). Since it has been suggested that expression of
RIP3 correlates with the functional relevance of programmed necrosis
in certain cell types,9 we hypothesized that RIP3 may also play a signifi-
cant role in the heart. Adenoviral overexpression of RIP3 led to a shift
in its molecular weight, indicating activation of RIP3.20 As a negative
control, this shifted band could be inhibited by RIP3-specific synthetic
miRNA (Figure 1C). As a positive control, we stimulated L929 mouse
fibroblasts that are particularly prone to programmed necrosis,9,20
with TNF-a and Z-Val-Ala-Asp-FMK (zVAD) caspase inhibitor. After
3 h of stimulation, immunoblots from these cells revealed the shifted
band at the same molecular weight as activated RIP3 in NRVCMs
(Figure 1D), suggesting that the molecular weight shift of RIP3 in
NRVCMs is indeed due to activation of RIP3. Analyses of NRVCMs by
confocal laser scanning immunohistochemistry confirmed endogenous
RIP3 expression in NRVCMs and showed perinuclear clustering of RIP3
(Figure 1D). In this regard, it has recently been reported that mitochon-
dria reveal perinuclear clustering during programmed cell death.21 Inter-
estingly, co-staining of NRVCMs with a RIP3 antibody and ‘Mitotracker’
revealed close co-localization of RIP3 and mitochondria in these cells
(Figure 1E–G). AdV RIP3 induced increased phosphorylation activity in
NRVCMs (Figure 2A). In contrast, overexpression of a kinase-dead
RIP3 mutant did not induce increased phosphorylation of RIP3, demon-
strating that adenoviral overexpression of RIP3 promotes kinase activity
of RIP3. As an additional indication of RIP3 activation, immunoblots
revealed increased polyubiquitination by Lys63 (K63) residue linkage
at the level of activated RIP3 (+151.9% vs. lacZ +24.9%, Figure 2B
and C ).
3.2 Overexpression of RIP3 induces the
formation of RIP1/RIP3 complex and
necrosis of cardiomyocytes
Cell culture experiments in human cell lines showed that association of
RIP1 and RIP3 in response to TNF-a stimulation represents the crucial
initial step inprogrammednecrosis.8,12 To testwhetherTNF-dependent
formation of RIP1/RIP3 complexes is also present in cardiomyocytes, we
infected NRVCMs with an adenoviral vector encoding for rat RIP3
(NCBI Reference Sequence: NM_139342.1) or GFP (green fluorescent
protein) as control. Forty-eight hours after infection, NRVCMs were
pretreated with a 50 mM zVAD-fmk caspase inhibitor, since caspases
have been shown to inhibit RIP3–RIP1 complex formation in vitro,12
and stimulated with 100 ng/mL of recombinant TNF-a for different
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time intervals. Immunoprecipitation with a RIP1 antibody followed by
immunoblotting with a RIP3 antibody revealed rapid formation of
RIP1/RIP3 complexes as early as 30 min after TNF stimulation with a
maximum at 60 min (Figure 3A). As a sign of increased turnover of
RIP1/RIP3 complexes in RIP3 overexpressing NRVCMs, RIP1 content
was significantly decreased in these cells (287.6+2.7%, P, 0.001,
n ¼ 3; Figure 3B and C). Next, we assessed the consequences of RIP3 ac-
tivation on cardiomyocyte survival. Of note, adenoviral overexpression
Figure1 RIP3 is expressed in cardiomyocytes. (A) Immunoblot revealing RIP3 expression in the mouse heart. GAPDH was used as loading control. RIP3
expression in the heart is lower compared with lung and spleen, higher than in brain and kidney (n ¼ 3,B). (C) Immunoblot showing thatRIP3 is expressed in
NRVCMs. Adenoviral overexpression of RIP3 induced a shift of RIP3 in molecular weight (RIP3 OE). Both endogenous and weight-shifted RIP3 expression
could be inhibited by two miRNA viruses: miRIP3-1 and miRIP3-2, but not by overexpression with miRNA control virus (micon), demonstrating the spe-
cificity of the shifted RIP3-bar. (D) As a positive control, stimulation of L929 mouse fibroblast with TNF-a and zVAD induced a shift in the molecular weight
ofRIP3. (E)Confocal laser immunocytology: co-staining ofRIP3 (stainedred)anda-actinin in anNRVCM. InNRVCMs,RIP3 showedaperinuclearclustering
(F, stained green), similar to mitochondria (G, stained red). (H ) Co-staining of mitochondria and RIP3. n ¼ 3 independent experiments. Con: unstimulated
control; AdV RIP3: RIP3 adenovirus.
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of RIP3 significantly increased the amount of propidium iodide
(PI)-positive cells (68.9+1.2 vs. 26.8+1.3% in unstimulated control
cells, P, 0.01, Figure 3D and E), as measured by FACS analysis.
Notably, overexpression of a kinase-inactive RIP3 mutant (RIP3 K51A)
did not alter the proportion of PI-positive cells, demonstrating that
kinase activity of RIP3 is required for the induction of cell death of
NRVCMs (see Supplementary material online, Figure S1). Combined
7AAD/annexinV staining revealed no difference in apoptotic cell rates
between both groups (data not shown). Simultaneous TNF-a stimula-
tion and caspase inhibition by zVAD-FMK slightly decreased the
RIP3-dependent cell death rate (Figure 3E). However, neither TNF-a
stimulation nor caspase inhibition alone affected RIP3-dependent cell
death rate (see Supplementary material online, Figure S2), confirming
that RIP3-induced cell death is not executed via the ‘canonical’ apoptotic
caspase-dependent pathway. In line with the FACS analyses, adenoviral
overexpression of RIP3 markedly reduced survival of NRVCMs (257+
0.83% vs. control, P, 0.01, Figure 3F), as measured by another cell via-
bility assay (MTT assay) and significantly increased cell lysis, as measured
by augmented troponin T release into the cell culture media (2143+
337 pg/mL vs. 801+ 89 pg/mL, P, 0.01, Figure 3G). In contrast, adeno-
viral miRNA-based knockdown of RIP3 did not alter the basal cell death
rate of cultured cardiomyocytes (data not shown). This effect might
favour the concept that RIP3-dependent effects are confined to stress
conditions and aredispensable under basic conditions. Of note, miRNA-
based knockdown of RIP1 (see Supplementary material online, Figure
S2C) only weakly inhibited RIP3-dependent cell death (see Supplemen-
tary material online, Figure S2D), indicating that RIP1 activity is not
required for RIP3-mediated cell death of cardiomyocytes. In conclusion,
we demonstrate that RIP3 is sufficient for induction of programmed
necrosis in cardiomyocytes.
3.3 RIP3 expression is induced in myocardial
infarction
To probe for a potential pathophysiological role of RIP3 in vivo, we exam-
ined activation of RIP3-dependent signalling in a mouse model of MI.
Interestingly, 24 h after permanent ligation of the LAD, significantly
up-regulated RIP3 protein levels were detected in ischaemic mouse
hearts (+70.69+14.36%, P, 0.05, Figure 4A and B), consistent with ac-
tivation of RIP3-dependent signalling pathways in response to myocardial
ischaemia. Histological analyses revealed up-regulation of RIP3 especially
in the peri-infarct zone of the LV (Figure 3E), implying functional relevance
of RIP3 in myocardial infarction.
3.4 RIP3 mediates inflammation and ROS
generation after myocardial infarction
To further examine the functional relevance of RIP3 in MI, we subjected
RIP32/2 mice18 to permanent LAD ligation (n ¼ 22). This intervention
did not result in differences with regard to the survival rate compared
with WT controls (see Supplementary material online, Figure S3A).
Next, we evaluated the effects of RIP3 deficiency on biochemical, histo-
logical, and ultrastructural levels. Haematoxylin–eosin stainings of WT
and RIP32/2 hearts after MI are shown in Figure 5A. To examine the role
of apoptosis in RIP3-dependent remodelling, we measured caspase 3
cleavage in WT and RIP32/2 hearts 24 h after LAD ligation. By immuno-
histology and western blot, we did not detect alterations of caspase 3
cleavage in both RIP32/2 hearts and WT controls (Figure 5B–D). Fur-
thermore, stainings for Cd31 revealed a comparable decrease of endo-
thelial cells in the infarcted areas in both genotypes (Figure 5E). Likewise,
electron microscopy of both WT and RIP32/2 hearts revealed no
obvious morphological differences between both groups (Figure 5F). In
contrast, 4 days after infarction we observed a marked attenuation of in-
flammatory cell invasion into infarcted regions in RIP3-deficient hearts
(Figure 5B). Inflammation is a major consequence of myocardial ischae-
mia19 and —in contrast to apoptotic cell death—a pivotal concomitant
effect of programmed necrosis in vivo.9,12 We therefore systematically
assessed whether the degree of inflammation was decreased in
RIP32/2 hearts after LAD ligation. Indeed, CD3 staining and quantifica-
tion of T-cell invasion revealed a significantly lower number of inflamma-
tory cells in RIP32/2 hearts (Figure 6A and B). The decreased
inflammatory response of RIP32/2 hearts was accompanied by an un-
altered systemic level of leucocytes and T cells in RIP32/2 mice com-
pared with controls. Furthermore, we could not detect any
morphological alterations of livers, lungs, kidneys, and spleens of RIP3
and WT mice 4 days after LAD ligation (see Supplementary material
online, Figure S4). In addition to inflammation, generation of ROS has
been presumed to be another key mediator of RIP3-induced organ
damage.6,10 We therefore examined RIP32/2 hearts and WT controls
forROScontent 24 h after LAD ligation.RIP32/2 hearts revealed signifi-
cantly decreased ROS generation vs. WT hearts (2.31+0.58 vs. 5.32+
1.18, P, 0.05, Figure 6C). In a reverse approach, we also assessed culti-
vatedNRVCMsoverexpressingRIP3 forROScontentsbyFACSanalysis.
Figure 2 Increased phosphorylation and ubiquitination activity of
RIP3 in neonatal rat cardiomyocytes. (A) Semi-quantitative phospho-
gel staining showing increased phosphorylating activity in cells overex-
pressing RIP3. Overexpression of a kinase-dead RIP3 mutant (AdRIP3
A51 K) led to no increase of phosphorylation activity (n ¼ 3). (B)
Immunoblot revealing polyubiquitin chains formed by Lys63 (K63)
residue linkage at the level of activated RIP3 in NRVCMs that were
infected with a RIP3 adenovirus vs. control cells that were infected
with aLacZ virus (AdVLacZ), demonstrating increasedubiqitinationac-
tivityof activatedRIP3 (+151.9%vs. lacZ+24.9%,n ¼ 3,C). NRVCMs
overexpressing a kinase-deadRIP3 mutant (AdVRIP3 K51A)) servedas
negative control, and immunoblot against GAPDH served as loading
control. *P, 0.01.
RIP3 and myocardial infarction 209
Interestingly, these cells showed an increased ROS content (+25 +
3.6% vs. LacZ-expressing cells, Figure 6D), emphasizing the functional
role of ROS generation as a potential primary effector of RIP3 in the
heart. Taken together, ROS generation and inflammation could both
function as mediators of RIP3-dependent myocardial damage due to is-
chaemia. To further assess the role of altered cardiac energetics in RIP3-
dependent remodelling, we used 31P magnetic resonance spectroscopy.
We found a higher PCr/ATP ratio of RIP2/2 mouse hearts vs. WT con-
trols; however, the difference did not reach statistical significance (see
Supplementary material online, Figure S5). Thus, likely additional
mechanisms are also relevant in RIP3-dependent cardiac remodelling.
3.5 RIP3 mediates adverseremodelling after
myocardial infarction
To examine whether RIP3 impairs cardiac remodelling after MI, we
assessed cardiac morphology and function of RIP32/2 mice and WT
controls under basal conditions, 24 h, and 30 days post-MI by cardiac
Figure 3 RIP3 induces programmed necrosis of cardiomyocytes. (A) Adenoviral overexpression of RIP3 in NRVCMs stimulates the formation of a RIP1/
RIP3 complex, as shown by immunoprecipitation after stimulation with TNF-a and pre-incubation with the pan-caspase inhibitor zVAD-fmk. (B) Immuno-
blot revealing that adenoviral overexpression of RIP3 leads to a significant decline in RIP1 expression (287.6+2.7%, P, 0.001, n ¼ 3, C). (D) PI staining
and FACS analysis show significantly increased cell death of NRVCMs overexpressing RIP3. zVAD-fmk and TNF-a stimulation did not significantly alter the
proportion of PI-positive cells (E), n ¼ 4 independent experiments. (F) Treatment of NRVCMs with zVAD-fmk and TNF-a did not significantly alter cell
viability, whereas overexpression of RIP3 in NRVCMs markedly decreased cardiomyocyte survival (n ¼ 4). (G) Overexpression of RIP3 in NRVCMs lead to
a significant increase of cell lysis, as measured by troponin T release into culture media (n ¼ 4). Con: unstimulated control; AdV GFP, AdV LacZ: control
adenovirus; AdV RIP3: RIP3 adenovirus; AdV RIP3 K51A: RIP3 virus expressing a kinase-inactive RIP3 mutant; PI: propidium iodide; FL2H: fluorescence
signal (high); FSC-H: forward scatter; *P, 0.05; †P, 0.01; ‡P, 0.001.
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MRI (Figure 7 and see Supplementary material online,Movies). Basic mor-
phological and functional parameters were comparable between both
groups (Table 1). Noteworthy, gadolinium-enhanced MRI scans of the
left ventricle 24 h after LAD ligation and histology-based quantification
of fibrotic areas 30 days after LAD ligation showed no significant differ-
ences in infarct size between both groups (Figure 7B and D, and see Sup-
plementary material online, Figure S6).
However, 30 days after LAD ligation, RIP32/2 mice demonstrated a
significantly better ejection fraction than WT controls (45+3.6%,
n ¼ 11 vs. 32+ 4.4%, n ¼ 10, P, 0.05; Figure 7F). Consistently,
RIP32/2 hearts showed less hypertrophy than WT controls, as demon-
strated by a decreased LV/body weight ratio (3.50+0.13 mg/g, n ¼ 11
vs. 4.20+0.21 mg/g, n ¼ 10, P, 0.05; Figure 7G). Moreover, real-time
PCR experiments revealed lower levels of B-type natriuretic peptide
(BNP) expression in RIP3-deficient hearts (Figure 7E) and serum tropo-
nin T levels were significantly lower in RIP3-deficient mice (see Supple-
mentary material online, Figure S3B), also consistent with improved
myocardial remodelling of these mice post-infarction. Taken together,
these data indicate that RIP3 does not alter short-term infarct size, but
promotes long-term adverse post-infarct remodelling in vivo.
4. Discussion
Programmed necrosis mediated by RIP3 has recently been identified as a
novel mechanism of cell death with major functional importance in
several organs, including liver,12 pancreas,9 and bowel.13 We here
show that RIP3 is also expressed in the heart, forms a complex with
RIP1 in cardiomyocytes, and can be activated upon TNF stimulation.
Nevertheless, cardiomyocytes appear to be less prone to necroptosis
compared with, e.g. Jurkat cells,12 since caspase inhibition and TNF-a
stimulation alone were not sufficient to induce significant cell death. In
contrast, forced overexpression of RIP3 is a potent stimulus for necrop-
tosis of NRVCMs, in line with the hypothesis that protective effects may
act upstream of RIP3. For example, inhibition of the RIP1/RIP3 complex
by caspase 8 has recently been suggested as one possible mechanism
protecting cells from necroptosis.22,23 The need of RIP3 overexpression
Figure4 RIP3 is up-regulated in ischaemic hearts. (A and B) Immunoblot demonstrating significant up-regulation of RIP3 24 h after permanent ligation of
the LAD in mouse hearts (n ¼ 4). (C ) Representative immunohistological staining of RIP3 in a sham-operated WT mouse heart. (D) As a negative control,
RIP32/2 mouse hearts were not stained by the RIP3 antibody. (E) 24 h after LAD ligation, WT hearts revealed increased staining of RIP3 in the peri-infarct
area (n ¼ 4).
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Figure5 Noaltered apoptosis rate in infarcted RIP32/2 hearts. (A)Representativehaematoxylin–eosin stainings ofWTandRIP32/2 hearts 48 h, 4 days,
and 30 days after LAD ligation. Scale bars denote 1000 mM. (B) Immunohistological stainings of both WT and RIP32/2 mouse hearts revealed discretely
scattered cells that were positive for cleaved caspase 3. (C) Immunoblot of WT and RIP32/2 protein extracts 24 h post LAD ligation showing no significant
difference in caspase 3 cleavage in both groups. Liver extract from LPS-treated TAK1 knockout mice 15 was used as positive control (pos con) for caspase 3
cleavage. The content of uncleaved caspase 3 was unaltered between both groups (n ¼ 4) (D). (E) As a marker of angiogenesis, both WT and RIP32/2
hearts showed an attenuated staining for Cd31 in infarcted areas. (F ) Representative electron microscopy imaging of border zones of infarcted areas of
WT and RIP32/2 mouse hearts 24 h after LAD ligation, revealing amorphous matrix densities. n.s.: no statistically significant difference.
M. Luedde et al.212
to detect the RIP1/RIP3 complex in NRVCMs may be due to a faster
turnover of complexes, e.g. due to rapid RIP1 cleavage12 in NRVCMs
compared with Jurkat cells. Consistently, we demonstrated that RIP3
overexpression leads to a significant decrease of RIP1 protein content
in NRVCMs. Another explanation might be based on low RIP3 expres-
sion in the heart under basal conditions, which hampers detection of the
RIP1/RIP3 complexes in NRVCMs. Up-regulation of RIP3 under stress
conditions (Figure4A) implies that a functional relevance of RIP3 and pro-
grammed necrosis in the heart is limited to stress situations like myocar-
dial ischaemia. In line with this notion, RIP32/2 mice show normal life
span and fertility18 as well as normal cardiac function under basal condi-
tions. Moreover, miRNA-based knockdown of RIP3 in NRVCMs did not
alter viability of NRVCMs compared with LacZ-infected control cells
(data not shown) and knockdown of RIP3 did have no effect on
TNF-a-stimulated NRVCMs (see Supplementary material online,
Figure S2). In this context, complex formation of RIP1 and RIP3 and sub-
sequent induction of programmed necrosis due to RIP3 overexpression
may mimic stress situations, consistent with the occurrence of pro-
grammed necrosis in cardiomyocytes.
The complex formation of RIP1 and RIP3 as early as 30 min after
TNF-a stimulation of NRVCMs as well as up-regulation of RIP3 24 h
after myocardial ischaemia imply that RIP3-dependent effects are exe-
cuted in an early response to exogenous stress. Recent work by Oerle-
mans et al.15 demonstrates a reduction of infarct size due to chemical
inhibition of RIP1 by Nec-1 24 h after induction of ischaemia. Consist-
ently, we could demonstrate the ‘canonical’ pathway of TNF-induced
complex formation of RIP1 and overexpressed RIP3 in NRVCMs.
However, overexpression of RIP3 alone was sufficient to induce
programmed necrosis of NRVCMs without a need for additional stimu-
lation by TNF-a (Figure 3). In this regard, cardiomyocytes differ from
other cells, e.g. L929 cells. In these cells, RIP3 overexpression requires
additional TNF-a stimulation to induce programmed necrosis.24 Two
explanations for this interesting result are possible:
first, RIP3 overexpressed in NRVCMs is constitutively active, ‘bypass-
ing’ the upstream TNF-related activation pathway. This explanation is
supported by the fact that knockdown of RIP1 did not significantly
inhibit RIP3-dependent cell death of cardiomyocytes either (see Supple-
mentary material online, Figure S2C), demonstrating a RIP1-independent
effect of RIP3 in cardiomyocytes.
Secondly, in the heart, additional yet unknown activation pathways of
RIP3 might exist apart from TNF-a. In this regard, recent studies demon-
strated that several different receptors and signalling pathways upstream
from RIP3 may activate necroptosis.25 The specific activation pathway of
RIP3 seems to be cell type-dependent and also depending on the specific
activating stress stimulus.25 In respect to our model of myocardial is-
chaemia, this explanation is supported by the fact that we did not find
significant differences in the regulation of TNF-a-related genes
between WT and RIP2/2 mouse hearts (see Supplementary material
online, Figure S7). Moreover, treatment of WT and RIP32/2 hearts
with the TNF-a inhibitor, etanercept, did not effectively rescue WT
mice after LAD ligation (data not shown). Thus, most likely other up-
stream pathways apart from TNF mediate RIP3 activation in myocardial
ischaemia.
In contrast to these early effects of RIP1 inhibition in the model of
Oerlemans et al., infarct size of RIP32/2 mice is not altered in our
model. At first sight, it is therefore surprising that RIP3 nevertheless
Figure 6 RIP3 mediates inflammation and generation of ROS in myocardial infarction. (A) RIP32/2 hearts revealed a significantly decreased invasion of
CD3-positive cells 4 days after LAD ligation vs. WT controls. (B) Scale bars denote 100 mM. (C) RIP32/2 hearts revealed significantly decreased levels of
ROS vs. WT controls 24 h after LAD ligation (n ¼ 8). (D) In line with this ROS-generating effect of RIP3 in vivo, neonatal rat cardiomyocytes overexpressing
RIP3 showed a moderately increased ROS production compared with NRVCMs expressing a control virus (LacZ, n ¼ 4). LV: left ventricular weight; Lig.:
LAD ligation. *P, 0.05.
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mediates long-term cardiac remodelling as well as contractile function.
Yet, a significant difference between programmed necrosis and apop-
tosis is the strong inflammatory response driven by necrosis.12 Consist-
ently, we could demonstrate that the post-ischaemic inflammatory
response of RIP32/2 mice is markedly decreased compared with WT
mice. Thus, apoptotic cell death was unlikely to account for the differ-
ences between both groups. Moreover, we could not detect any
evident change in apoptotic cell death between both groups, as measured
by caspase 3 cleavage. Since a role of inflammation in post-infarction
remodelling has been demonstrated before,26 reduced inflammation
may be one possible mechanism for the observed protective effects of
RIP3 ablation on adverse remodelling in our study. This mechanism
seems to be heart-specific, as the total count and proportion of T cells
in the blood of RIP32/2 mice was unaltered compared with WT mice.
Figure 7 RIP3 mediates adverse left ventricular remodelling in response to myocardial ischaemia. (A) Cardiac MRI from WT and RIP32/2 mice under
basal conditions. (B) Gadolinium-enhanced MRI short-axis views of WT and RIP32/2 hearts 24 h after LAD ligation, showing that infarct size is not altered
between both groups, as quantified in (D) (n ¼ 4). (C) MRI short-axis views 30 days after LAD ligation, scale bars: 5 mm. Thirty days after LAD ligation,
RIP32/2 hearts revealed a significant down-regulation of BNP vs. WT controls, a significantly better ejection fraction (EF) (E) and less hypertrophy (F)
than WT controls (n ¼ 12, *P, 0.05, †P, 0.01).
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However, since our results are based on the constitutive knockout of
RIP3, we cannot definitely rule out that RIP3 deficiency of leucocytes
may have a cardiomyocyte-independent effect in this regard.
In addition to a decreased inflammatory response, we could demon-
strate decreased generation of ROS in RIP32/2 mice after LAD ligation
(Figure6C). Generationof ROShas been considered acrucial mechanism
of RIP3-induced cell damage.8,10 In our model of permanent myocardial
ischaemia, ROS might be a key mediator that ‘translates’ short-term
effects of RIP3 signalling into long-term adverse ischaemic remodel-
ling.27 Oxidative stress has been demonstrated to activate prohyper-
trophic signalling pathways like mitogen activated protein kinases28
and to cause a slippage of myofibrils and LV dilation,29 ultimately
leading to decreased ventricular contractility. Thus, inhibition of ROS
generation is likely to be causative for preserved contractility in the
RIP3 knockout mouse. Of note, oxidative stress also induces inflamma-
tory pathways in the heart;29 thus, the relative contribution of these two
mechanisms to RIP-mediated LV remodelling cannot be considered in-
dependently. Mitochondria have been recognized to be a source of ex-
cessive ROS generation in MI.28 The co-localization of RIP3 and
mitochondria implies that mitochondrial ROS generation is crucial in
RIP3-dependent myocardial remodelling. In line with this notion,
several recent publications have identified the mitochondrial proteins
such as mixed lineage kinase domain-like protein (MLKL) and phospho-
glycerate mutase family member 5 (PGAM5) as downstream effectors of
RIP3.20,30– 33 These results have even led to the consideration of the
RIP1/RIP3 complexbeing a ‘mitochondrial attack complex’,20,30 with dis-
sipation of the mitochondrial transmembrane potential (DcM) ultimate-
ly leading to fragmentation of mitochondria under specific stress
conditions32 Indeed, we could detect a trend towards improved ener-
getics of RIP32/2 mouse hearts after LAD ligation in vivo. Moreover,
the co-localization of RIP3 and mitochondria in cardiomyocytes is con-
sistentwith the functional importanceof mitochondria in RIP3-mediated
cardiac damage. However, RIP3 overexpression in cardiomyocytes did
neither cause fragmentation of mitochondria nor significant alteration
of the mitochondrial transmembrane potential (DcM) compared with
control cells (data not shown). As possible explanations for this interest-
ing finding, ROS might be generated by other sources, like endosomes,34
peroxisomes,35 or infiltrating immune cells. In line with this assumption,
a novel report by Tait et al.36 generally challenges the functional role of
mitochondria inprogrammednecrosis, demonstrating that in somecells,
mitochondria arenot necessarily required in this process. It thus appears
possible that RIP3 may affect regulatory functions on metabolism apart
from mitochondrial damage, especially in an energy-dependent organ
like the heart.
In conclusion, we here demonstrate that RIP3 exerts negative effects
on post-ischaemic cardiac remodelling. In addition to the data of Oerle-
mans et al. on RIP1 in ischaemia–reperfusion injury, these results imply a
fundamental roleofpathways mediating programmednecrosis in cardiac
ischaemia. Because late cardiac remodelling with subsequent post-
ischaemic heart failure is still a major clinical problem, these signalling
pathways might represent attractive targets for future therapeutic inter-
ventions.
5. Limitations of this study
The in vivo results presented in this study are based on a constitutive
knockout of RIP3. Although we have not observed any morphological
differences between transgenic and WT control mice in peripheral
blood cells as well as other organs, we cannot definitely rule out that
RIP3 deficiencyof othercell types may havecontributed to the observed
effects in the heart. Moreover, our study does not provide a quantitative
comparison of apoptotic vs. necroptotic cell death in the course of myo-
cardial ischaemia. Thus, we cannot definitively conclude that necropto-
sis is the dominant form of cell death in post-ischaemic myocardial
damage. Nevertheless, we feel that the alterations of myocardial remod-
elling in the RIP3 knockout mouse strongly argue for an important role of
the necroptotic RIP3 signalling pathway in post-MI remodelling. Further
studies are needed to finally compare the relative contribution of each
form of cell death in this and other disease models.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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Table 1 Morphological and functional parameters of RIP32/2 mice hearts and WT controls under basal conditions and 30 days
post LAD ligation, assessed by MRI
WT RIP32/2
Basal 30 days post LAD ligation Basal 30 days post LAD ligation
Weight (g) 23.6+0.5 27.7+0.4 24.9+0.6 26.8+0.5
Heart rate (/min) 487+15.1 562+14.6 495+22.0 531+15.1
EDV (mL) 62+2.3 121+19.9 71+4.8 83+8.6
ESV (mL) 23+1.6 89+20.4 30+3.9 48+8.7
Stroke volume (mL) 39+1.3 32+1.8 42+1.6 35+1.4
Ejection fraction (%) 63+1.6 32+4.4 59+2.3 45+3.6*
Cardiac output (mL/min) 19+0.6 18+1.3 21+1.3 19+0.6
LV weight (mg) 89+4.0 116+6.0 84+2.3 94+4.4*
LV/body weight (mg/g) 3.6+0.1 4.2+0.2 3.6+0.1 3.5+0.1*
WT, wild type; EDV, end-diastolic left ventricular volume; ESV, end-systolic left ventricular volume; LV, left ventricular.
*P, 0.05 vs. WT.
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